Prostate Cancer

Despite Latino and Hispanic men being more likely to present with higher-risk prostate cancer, they are less likely to receive treatment for their disease compared to other ethnicities.

After experiencing cancer, I feel a profound sense of empathy for others in tough situations, from the war in Ukraine to COVID-19.

Treatment with androgen deprivation therapy in combination with Zytiga, docetaxel and prednisone improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.

While a higher risk of heart issues was found in older men years after androgen-deprivation therapy, it is unknown if the risk comes from the treatment or other age-related comorbidities.

John Wayne coined the term, “the Big C,” for cancer, but I think it’s time that the capital letter C stands for something better.

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

A recently FDA-approved drug offers patients with metastatic castration-resistant prostate cancer a newer treatment that improves survival, but is not curative of the disease, which means that more research is needed, according to an expert.

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

In a news release, Merck advised patients enrolled on the trial to consult with their health care provider regarding their treatment.

Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.

One expert noted that patients with prostate cancer can take a few months to make an informed treatment decision without impacting their long-term outcomes.

The STELLAR-002 trial is currently underway to examine the combination of XL092, an experimental tyrosine kinase inhibitor, in combination with immuno-oncology therapies for patients with advanced solid tumors.

Prostate cancer survivors are encouraged to include their partners in interventions to improve sexual function after treatment — and, as study results show, it is better to have these conversations with providers sooner rather than later.

Sexual dysfunction may often happen after prostate cancer treatment, and the results of one study shown that an online program for both the patient and their partner may help in this aspect of recovery.

Additional advancements in how radical prostatectomy is performed are needed to improve other urinary outcomes such as good urinary function and social incontinence.

The pharmaceutical company announced preliminary results on a phase 3 trial, which demonstrated that Nubeqa with docetaxel and androgen deprivation therapy may improve overall survival in men with metastatic hormone-sensitive prostate cancer.

With recently revised treatment guidelines, doctors may be more likely to recommend active surveillance to men with low-risk prostate cancer.